These results led to the approval of BRAF plus MEK inhibitors for high risk resected (stage III) and advanced melanoma patients [9,10], underlining the importance of the early molecular characterization of high-risk stages II, III and IV melanoma patients, which is actually mandatory according to the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines [11] and represents a fundamental step for tailored therapy. Here, BRAF is linked to melanoma.